請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66576完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭明良 | |
| dc.contributor.author | Tsu-Yao Cheng | en |
| dc.contributor.author | 鄭祖耀 | zh_TW |
| dc.date.accessioned | 2021-06-17T00:44:11Z | - |
| dc.date.available | 2017-03-02 | |
| dc.date.copyright | 2012-03-02 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2012-01-11 | |
| dc.identifier.citation | Alldridge LC, Bryant CE. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. (2003) Exp Cell Res 290:93-107.
Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE. (1999).The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 274:37620-8. Babbin BA, Lee WY, Parkos CA, et al. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. (2006). J Biol Chem 281:19588-99. Bouvard D, Millon-Fremillon A, Dupe-Manet S, Block MR, Albiges-Rizo C. Unraveling ICAP-1 function: toward a new direction? Eur J Cell Biol. 2006;85:275-82. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. (2009). Crit Rev Oncol Hematol 71:127-64. Chang DD, Wong C, Smith H, Liu J. ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. (1997). J Cell Biol 138:1149-57. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. Characterisation and protein expression profiling of annexins in colorectal cancer. (2008). Br J Cancer 98:426–433. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Manual. 7th ed. (2010). New York, NY: Springer. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. (2004). Cancer Epidemiol Biomarkers Prev 13:667-72. Frey BM, Reber BF, Vishwanath BS, Escher G, Frey FJ. Annexin I modulates cell functions by controlling intracellular calcium release. (1999). FASEB J 13:2235-45. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. (2007). Atlanta, GA: American Cancer Society. Gerke V, Moss SE. Annexins: from structure to function. (2002). Physiol Rev 82:331-71. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. (2005). Nat Rev Mol Cell Biol 6:449-61. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. (2010). Cell 140:883-99. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. (2006). Blood 107:2123-30. Hu N, Flaig MJ, Su H, Shou JZ, Roth MJ, Li WJ, Wang C, Goldstein AM, Li G, Emmert-Buck MR, Taylor PR. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. (2004). Clin Cancer Res 10:6013-22. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. (2005). Postgrad Med J 81:419-24. Jinawath N, Furukawa Y, Hasegawa S, Li M, Tsunoda T, Satoh S, Yamaguchi T, Imamura H, Inoue M, Shiozaki H, Nakamura Y. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. (2004). Oncogene 23:6830-44. Liakakos T, Roukos DH. More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. (2008). Ann Surg Oncol 15:956-60. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. (2001). Cell Signal 13:777-85. Lim LH, Pervaiz S. Annexin 1: the new face of an old molecule. (2007). FASEB J 21:968-75. Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, Chiang CP, Kuo MY. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. (2008). J Surg Oncol 97:544-50. Lin MT, Chang CC, Lin BR, Yang HY, Chu CY, Wu MH, Kuo ML. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. (2007). J Biol Chem 282:34594-604. Liu S, Calderwood DA, Ginsberg MH. Integrin cytoplasmic domain-binding proteins. (2000). J Cell Sci 113:3563-71. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. (2006). Cytokine Growth Factor Rev 17:501-19. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. (2008). J Pathol 216:131-40. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. (1996). Br J Cancer 74:1406-12. Oh J, Rhee HJ, Kim S, Kim SB, You H, Kim JH, Na DS. Annexin-I inhibits PMA-induced c-fos SRE activation by suppressing cytosolic phospholipase A2 signal. (2000). FEBS Lett 477:244-8. Perretti M, Chiang N, La M, La M, Fierro IM, Marullo S, Getting SJ, Solito E, Serhan CN. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. (2002). Nat Med 8:1296-302. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. (2009). Nat Rev Immunol 9:62-70. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. (2003). Cancer Metastasis Rev 22:395-403. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. (2005). N Engl J Med 353:1711-23. Rodrigues-Lisoni FC, Mehet DK, Peitl P Jr, Mehet DK, Peitl P Jr, John CD, da Silva Junior WA, Tajara E, Buckingham JC, Solito E. In vitro and in vivo studies on CCR10 regulation by Annexin A1. (2006). FEBS Lett 580:1431-8. Saper CB, Sawchenko PE. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. (2003). J Comp Neurol 465:161-3. Taiwan Cancer Registry Annual Report, 2008. (2008) Bureau of Health Promotion, Department of Health, R.O.C. (Taiwan) Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T. Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). (2004). Cancer Res 64:6065-70. Ura H, Denno R, Hirata K, Yamaguchi K, Yasoshima T. Separate functions of alpha2beta1 and alpha3beta1 integrins in the metastatic process of human gastric carcinoma. (1998). Surg Today 28:1001-6. Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browing JL, Ramachandran KL, Pepinsky RB. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. (1986). Nature 320:77-81. Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. (2000). Mol Cell 5:831-40. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. (2006). Clin Cancer Res 12:4598-604. Williams SL, Milne IR, Bagley CJ, Gamble JR, Vadas MA, Pitson SM, Khew-Goodall Y. A proinflammatory role for proteolytically cleaved annexin A1 in neutrophil transendothelial migration. (2010). J Immunol 185:3057-63. Wu CM, Lee YS, Wang TH, Lee LY, Kong WH, Chen ES, Wei ML, Liang Y, Hwang TL. Identification of differential gene expression between intestinal and diffuse gastric cancer using cDNA microarray. (2006). Oncol Rep 15:57-64. Wu MS, Lin YS, Chang YT, Shun CT, Lin MT, Lin JT. Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection. (2005) World J Gastroenterol 11:7405-12. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. (2003). Am J Pathol 162:255-61. Xue LY, Teng LH, Zou SM, Ren LQ, Zheng S, Luo W, Bi R, Lu N. Expression of annexin I in different histological types of carcinomas. (2007). Zhonghua Zhong Liu Za Zhi 29:444-8. Yi M, Schnitzer JE. Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. (2009). Proc Natl Acad Sci U S A 106:17886-91. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. (2000). Br J Surg 87:236-42. Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. (2008). Clin Exp Metastasis 25:695-702. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R, Howard OM, Farrar W, Wang JM. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. (2005). J Natl Cancer Inst 97:823-35. Zhu F, Xu C, Jiang Z, Jiang Z, Jin M, Wang L, Zeng S, Teng L, Cao J. Nuclear localization of annexin A1 correlates with advanced disease and peritoneal dissemination in patients with gastric carcinoma. (2010). Anat Rec 293:1310-4. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66576 | - |
| dc.description.abstract | 胃癌在世界癌症死因之中位居第二，而在台灣癌症死因中排名第六。即使近年癌症治療學的進步，晚期胃癌的治療預後依然不佳。最近利用雷射顯微細胞組織擷取術合併cDNA微陣列分析來進行基因表現的研究，發現膜聯蛋白A1基因在胃癌中因為有好的再現性，可望作為一癌症指標。膜聯蛋白A1已廣為人知是一受到腎上腺醣皮質素調控的抗發炎蛋白，可以藉由抑制細胞質內磷酸酶A2α來阻礙花生四烯酸的釋出以及下游產物類花生酸的形成。最近愈來愈多的證據暗示膜聯蛋白A1有著更多的細胞功能，諸如膜間聚集效應、胞噬作用、細胞增生、細胞凋亡、甚至腫瘤生成。過去已有多篇研究顯示，在肝癌、食道腺癌、大腸癌、胰癌中可見到膜聯蛋白A1之表現增加，在乳癌、攝護腺癌以及食道鱗狀上皮細胞癌中卻看到膜聯蛋白A1之表現減少。這些研究意喻著膜聯蛋白A1在腫瘤生成的過程中，有隨著腫瘤種類不同而表現形態不同的專一特性。然而目前膜聯蛋白A1在胃癌的角色上仍未有定論，而相對應的調控機制也不清楚。本篇研究發現在胃癌中膜聯蛋白A1的高度表現會和腹膜腔轉移(p值0.009)以及漿膜層侵犯(p值0.044)有顯著的相關性。寇克斯多變量分析顯示胃癌病患之膜聯蛋白A1的高度表現，對於總存活率是一項獨立的危險因子(p值0.037)。細胞實驗中，膜聯蛋白A1的表現量與胃癌細胞的侵襲性呈現正相關。此外，在小鼠的生體實驗中，利用皮下植入以及腹膜腔內注入模型，同樣可見膜聯蛋白A1的表現會增加胃癌細胞的侵襲性。在調控機制的研究方面，本研究發現膜聯蛋白A1會透過FPRs/ERK/ITGB1BP1途徑來調控胃癌的侵襲性，而所有已知的三種甲醯肽受器FPR(包括FPR1-3)都對調控過程有所影響。此研究結果暗示膜聯蛋白A1的表現可以作為預測胃癌病人預後之用。本研究也發現藉由甲醯肽受器FPR、ERK1/2、以及ITGB1BP1這些分子，有一膜聯蛋白A1用以調控胃癌侵襲性的新機制。 | zh_TW |
| dc.description.abstract | Gastric cancer is the second leading cause of cancer-related death in the world and the sixth leading cause of cancer-related death in Taiwan. The prognosis of advanced gastric cancer remains poor despite the improvement in therapeutic options. In the recent studies of gene expression profiling of gastric cancer cells by cDNA microarray with laser capture microdissection, annexin A1 (ANXA1) gene was identified to be a potential marker in gastric carcinogenesis with good reproducibility. AnxA1 has been well-known as a glucocorticoid-regulated anti-inflammatory protein in blocking the release of arachidonic acid and its subsequent conversion to eicosanoids by inhibition of cytosolic phospholipase A2α. More and more evidence suggests that AnxA1 has a wide variety of cellular functions, such as membrane aggregation, phagocytosis, proliferation, apoptosis and even tumorigenesis. Previous studies have shown increased AnxA1 expression in patients with hepatocellular carcinoma, adenocarcinomas of the esophagus, colon and pancreas, but reduced in adenocarcinoma of the breast and prostate, as well as in squamous cell carcinoma of the esophagus and head and neck. These studies suggest AnxA1 to be implicated in tumorigenesis in a tumor type-specific pattern. However, the role of AnxA1 in gastric cancer is indeterminate, and the underlying mechanism is not clear. In this study, we found that high AnxA1 expression was significantly associated with peritoneal metastasis (p=0.009) and serosal invasion (p=0.044) in gastric cancer. Cox multivariate analysis showed that high AnxA1 expression was an independent risk factor for poor overall survival in gastric cancer patients (p=0.037). AnxA1 expression positively correlated with invasiveness of human gastric cancer cells in vitro. Besides, we applied both subcutaneous implantation and intraperitoneal inoculation models in mice and found that AnxA1 would potentiate gastric cancer cell invasiveness in vivo. For the mechanistic evaluation, our study showed that AnxA1 could regulate the gastric cancer cell invasiveness through the formyl peptide receptors (FPRs)/ERK/ITGB1BP1 pathway; and all three FPRs (FPR1-3) were involved in the regulation process. These data suggested that AnxA1 expression may be used to predict patient outcome in gastric cancer. Furthermore, the current study demonstrated a novel mechanism involving FPRs, ERK1/2, and ITGB1BP1 by which AnxA1 regulated gastric cancer cell invasiveness. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T00:44:11Z (GMT). No. of bitstreams: 1 ntu-100-D94447004-1.pdf: 2582691 bytes, checksum: b887424abca26ae5231530e3ff3edcd0 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | Introduction...............1
Materials and Methods......5 Results...................12 Discussion................17 Tables....................22 Figures and Legends.......26 References................43 Appendix..................50 | |
| dc.language.iso | en | |
| dc.subject | 總存活率 | zh_TW |
| dc.subject | 胃癌 | zh_TW |
| dc.subject | 膜聯蛋白A1 | zh_TW |
| dc.subject | 甲醯肽 | zh_TW |
| dc.subject | 受器 | zh_TW |
| dc.subject | 侵襲性 | zh_TW |
| dc.subject | gastric cancer | en |
| dc.subject | annexin A1 | en |
| dc.subject | formyl peptide receptor | en |
| dc.subject | invasiveness | en |
| dc.subject | overall survival | en |
| dc.title | 探討膜聯蛋白A1對胃癌侵襲性之影響 | zh_TW |
| dc.title | The Impact of Annexin A1 on Gastric Cancer Invasiveness | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 林明燦,吳明賢,葉松鈴,王朝鐘 | |
| dc.subject.keyword | 胃癌,膜聯蛋白A1,甲醯肽,受器,侵襲性,總存活率, | zh_TW |
| dc.subject.keyword | gastric cancer,annexin A1,formyl peptide receptor,invasiveness,overall survival, | en |
| dc.relation.page | 52 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-01-11 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 毒理學研究所 | zh_TW |
| 顯示於系所單位： | 毒理學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 2.52 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。